1 published article · Updated continuously
12 trials tracked for Mania: 9 in phase 3 or 4 and 3 with published results. The most-cited published study has 119 citations.
Showing the 12 most-cited and recently-updated of 12 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
Lithium treatment for mania was associated with specific Sedation Scores ranging from 0.4 to 0.6 and YMRS scores between 14.3 and 21.4 1. Quetiapine demonstrated significant reductions in YMRS total scores, including a reduction of -20.72 at the end of treatment (Day 21) for a 600mg dose 3, and a reduction of -14.5 in bipolar symptoms as measured by Y-MRS 5.
Cariprazine showed statistically significant improvements in mania symptoms at week 3. Specifically, it resulted in YMRS score reductions ranging from -12.5 to -19.6 (p<0.001; p=0.0004) and CGI-S score reductions of -1.3 to -1.9 (p<0.001; p=0.0027) [6, 7].
Lamotrigine was evaluated in the context of mania and alcohol use, showing a reported abstinence rate of approximately 78-80% and a reduction in heavy drinking days to between 8.1% and 11.6% [2, 4].
AI synthesis of 3 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
